{"name":"AL-S Pharma","slug":"al-s-pharma","ticker":"","exchange":"","domain":"","description":"AL-S Pharma is a biotechnology company focused on the development of innovative therapies, with a current pipeline centered around AP-101, which is in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AP-101","genericName":"AP-101","slug":"ap-101","indication":"Major depressive disorder","status":"phase_2"}]}],"pipeline":[{"name":"AP-101","genericName":"AP-101","slug":"ap-101","phase":"phase_2","mechanism":"AP-101 is a small molecule that targets the serotonin receptor.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOVHBJRDBWYm5XN3FaSUY2d3JTNXI1ZFdtSC1PMkp4SjRiektVRk1XcTNtVjRqV09XTnN1OFdzZGtyMWE1eVgxRk93eGtVcnRGN1U5Z1hvNlZMaE85VUNmY0RuOVY0NWljZWw3MTJNQ3pFYkI3azZmRUp3Qkc0MTBXM1B3?oc=5","date":"2026-04-03","type":"deal","source":"NJBIZ","summary":"Shionogi completes $2.5B deal for ALS drug Radicava rights - NJBIZ","headline":"Shionogi completes $2.5B deal for ALS drug Radicava rights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNVjM1NURaRHBjWXZSSmpwSnJMSmFLQ3NKTTJvUUxkZnMzdFE2SUg2SmdFMC1nSExvTndHZ2ZESFMwZm8yRHpVZkxWNTBzYTU2X0h2d2lqSTFpWmd0RUQyVDNLbTkyUDUzaldDSzVrUUxScy0yS1AxLXZSSWRqY216RXpXaUR5a2FQYVduNm9CdTZBS2s0OVQ5ZnkwTQ?oc=5","date":"2026-03-25","type":"trial","source":"ALS News Today","summary":"New ALS treatment improves survival, leads to function gains in trial - ALS News Today","headline":"New ALS treatment improves survival, leads to function gains in trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPamdIbks1MFU2RHRQQV8wYndLbDNzWElsaWxMblNKalFmNDJfMDFHMFFpY1J2a2hwTzZQbkRxdHFYWGZvMjYtWVRjV1M5SjNnVVFrT0N0SklvcTFYY09VRnFSNHhtNVdsU3VmRC1zLWU2X2g3OXVZZDZiMjlHZXlQMS1CYTN3N1lHN2ktaGtyUDVJZ1VXbkdoS0ZIVERZd1lWcnMzelFyNnFXUnZOZVQ1UkNUNzk5X3FObW1CUjFvTTVKZHdDQ08xS2t1WC1zYlFt?oc=5","date":"2026-03-24","type":"trial","source":"Clinical Trials Arena","summary":"AD/PD 2026: AL-S Pharma’s AP‑101 data backs approach to target misfolded SOD1 in ALS - Clinical Trials Arena","headline":"AD/PD 2026: AL-S Pharma’s AP‑101 data backs approach to target misfolded SOD1 in ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxQdmVyS3lqb2NkTU0yVEJobGxJdXZVYy1SVHlDTi1zRFpWYVhCRDRCRjNab3B4TUhYc3k3aGF5bDhJT25nQk1WeWFYSTJibE1SWWtKUDJXOEdfSmNTTHMyMUxFUks5RUVRbXpoZDY0T09PYzl2REd3NWlSdDRrV1R5VUl3OHpwYUg4N1JlS1o0UmlQYllhbkozaFNnYlY5V1hvUzNLS29SQWotNnN0eVFXaU44ZHNtNnFRT29pd2J6V3RuMy1LcUNjTC1femdSX0YtVTZpYlIxdzdiTUppVll1N2tyRXFicWlIMHVYZEdSdm0xRG4yZ0tvRlYteDFDUVNQWnBKWkZvejhFWHd1UjF4TVBuODcwS0hjVWRZZEJsRlRJSy1DWEhJSW5icXM5VEx6WDNN?oc=5","date":"2026-03-19","type":"trial","source":"Business Wire","summary":"Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS - Business Wire","headline":"Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modificat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNWDZweHUxNGJTRWpMRFc0UEMwNGpYWmI2ckVURkl6b0FmcFBrYUxzM0RRNHlKNlA0aVptRlBpWXQ4SDB5Q2picWRUbTNBZGhKUU9YOUFJZUZJTXdGN1oyR2FMREFfWngxYzRNelJRcjVwQ0N5Qml0MU5ETV9BZEJtLXV1VUVJcFpsV3VDU3MzU0ZxY05jcGRZTThnU2k4MlBwdHBzY3d3RW10c2U2MTBVNGR0Q1d2dw?oc=5","date":"2026-03-16","type":"pipeline","source":"Mass General Brigham","summary":"Experimental Therapy Shows Safety and Signals of Clinical Benefit in ALS - Mass General Brigham","headline":"Experimental Therapy Shows Safety and Signals of Clinical Benefit in ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTFA3czdwNmR5WkQ5cHJ5eFkwNEZWYU5OVnBuVlpEcDdRMVF4bmRLbEJfU0NNTFdhczZVeXkyYmEzaHo4czFSNzFuV0ppZE9FdC1BMXpBb3c0RlB3VXV0YXJUOHhR?oc=5","date":"2026-01-19","type":"pipeline","source":"Labiotech.eu","summary":"10 promising biotechs racing toward a cure for ALS - Labiotech.eu","headline":"10 promising biotechs racing toward a cure for ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPdHZBLWN3LVpzc1VJOTJoTWxiMmYzTGk3NUpEeHdfMnM0OURFRWFOdUYtWFZrWWRCNlNFM002U1hTVV96eTQzN3lGTk5uXzN4c1VNaWdtQzBaTkZ4MHo5YlA4OGp1a1ZqejE3YkF4Wm9XSExPamQxTzFTVVgzdHZCbWtvNDIteC1PWEdvcGZR?oc=5","date":"2025-12-08","type":"trial","source":"Clinical Trials Arena","summary":"AL-S takes mAb to Phase III after mid-stage ALS success - Clinical Trials Arena","headline":"AL-S takes mAb to Phase III after mid-stage ALS success","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQbEpJT1lBYjRaTWxZSE96T0dqRzJtYVVkRGVPN09oT1VuV3BZRDliTXcwalNGeG5GUHQxaEttZWdGdWdBTklyY2ZVTU41clZYMVJOUGdXSnZ4bk5JcU8waFNjWWpjaUxoZ1puSE4ySk03NzRoMXJpQU41ekJJZGtFcmEydF9pcGptQjh2ZXRVbDhlU25GZV9iUjR1Sy05RHJvSHVsRXJfbDc3WHdsaGx3U21WcV9jOFNXbUZoQjFaaUo3empYNnJqd3gzYzJZekVQd3FZdVVxZ0hNclh1cDZZaFBERUxidGIyWEdQWVRMZDhhVkNHeXVSR1ZzOHNEMjR2YklYU0tGQlE5VlEweTdvbzZTUjJqNEQzUHZxUzFUZ3p4UQ?oc=5","date":"2025-12-05","type":"trial","source":"PR Newswire","summary":"AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study - PR Newswire","headline":"AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNUTFnem8xNlVHNndraktOUmd4U3ZMS0F2bWU4c2lnTEdxUlZwdVotb211RHY3RFBIQlNOUC1XdHFzWGRnY19INFpDbDZCU2pZQ2RMUllmamdHZnluN2ZWaDRtN0diektXSVhLdXhVZ1FxeW82OURUNXJpc2ZkZHd2a3JzMXZfcWFLQXRjbkZmNmF3Q2ViS1p2NA?oc=5","date":"2025-10-07","type":"regulatory","source":"Pharmaceutical Technology","summary":"FDA lifts clinical hold on Neurizon’s ALS drug - Pharmaceutical Technology","headline":"FDA lifts clinical hold on Neurizon’s ALS drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOSGZ4YTFvQWRzVnRpS051V1Uyc2J0TkFIcFRlRlRHcUk5QkUtam4xRXV0TGdUaVFVQ1pVSDJSMUxiLXU3Zlg1QkE4Z0E0cmdiNS1sRjlsMUlkZWZmQ1hvSl9PNXN3Q3NhTjRXODBNdGtTT09yZ2xPUXU5VWxFSzM5c09XSVFDZw?oc=5","date":"2025-09-25","type":"pipeline","source":"The Pharma Letter","summary":"AL-S Pharma names Angela Genge CMO - The Pharma Letter","headline":"AL-S Pharma names Angela Genge CMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQdnFnYWY2RldDblVidnduaGJTMnQ0Mm5NZGRaTC1kbGV3WHhPay1hYV8zTi1pLWJpdHFNc2dMVldDenBBOGhqX29mcjIxcEd4aGd3MERTeVpqWFcxZTlKMmhmcjVkRDdocExDWTdKZUYyZ2I5T0NKWEJBNDctWHpkRWQ5TDBFXzF0c3NxNXhrRUR2U3lNanRBNkxOWVRfNFZ2Mzd0RExkVGlXeUtDNmVoUkE2U3BndzFOVU5vdnRQRVhOWDVzVjF6cDZrWVR5VnJYUy1jd0RsYUFUSVZTTVFhS2FRVWNxWG1pTkxwUVhUMVFJSGZWWXZXaXNwNFM0dk41eHFxa3NwaC1sSlVuLWNyVEk1cEQ4dw?oc=5","date":"2025-09-25","type":"trial","source":"PR Newswire","summary":"AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer - PR Newswire","headline":"AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Me","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNblZHOFR2ZmhzNTBWM2xFU2U1MlBvTVg0QUtDSDFRdHJXX3NqaUV5Y0U2cl9xdW5meXR2aFp5RFVhRTd3MzJQMVY4YVBfWDFlM3RKUXpnZ2lTYlMyYUhhXzd5dnRNendIOVdGY1JRYm10ZnF1NDhGYnZMbVpmTkNOZlNIMkQ2dUllRE9PM3hHdTVsdw?oc=5","date":"2025-09-06","type":"trial","source":"neurologylive.com","summary":"AP-101 Meets Primary End Point in Phase 2 Study of SOD1 ALS - neurologylive.com","headline":"AP-101 Meets Primary End Point in Phase 2 Study of SOD1 ALS","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}